Genetically modifying the stem cells of HIV patients may one day prove to be an effective, one-time therapy against the hard-to-kill virus, according to the results of a proof-of-principle trial published this week in Science Translational Medicine.
In contrast to the widely used highly active antiretroviral therapy (HAART), which patients must continue for their entire lives to control the virus, such a genetic treatment has the potential to be "a single administration therapy," said bioengineer linkurl:David Schaffer;http://www.cchem.berkeley.edu/schaffer/ of the University of California at Berkeley, who was not involved in the trial, "where you introduce [a gene] into somebody's cells, and it stays there the rest of their lives. [That] has the potential to be a major plus," eliminating many of the toxic effects and financial costs of HAART. Because of these potential advantages, gene therapy -- the integration of new genetic material...
Image: Wikimedia commons,
The New England Journal of Medicine
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!